556 related articles for article (PubMed ID: 29094477)
1. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
Fiorini G; Saracino IM; Zullo A; Gatta L; Pavoni M; Vaira D
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 29094477
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population.
Miehlke S; Frederking D; Günther T; Glocker E; Eisele B; Andresen V; Schröder S; Morgner A
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28833925
[TBL] [Abstract][Full Text] [Related]
3. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
Zullo A; De Francesco V; Bellesia A; Vassallo R; D'Angelo A; Scaccianoce G; Sacco R; Bresci G; Eramo A; Tanzilli A; Ridola L; Alvaro D; Londoni C; Brambilla G; Manta R; Di Ciaula A; Portincasa P
J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433
[TBL] [Abstract][Full Text] [Related]
4. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
Nyssen OP; Perez-Aisa A; Rodrigo L; Castro M; Mata Romero P; Ortuño J; Barrio J; Huguet JM; Modollel I; Alcaide N; Lucendo A; Calvet X; Perona M; Gomez B; Gomez Rodriguez BJ; Varela P; Jimenez-Moreno M; Dominguez-Cajal M; Pozzati L; Burgos D; Bujanda L; Hinojosa J; Molina-Infante J; Di Maira T; Ferrer L; Fernández-Salazar L; Figuerola A; Tito L; de la Coba C; Gomez-Camarero J; Fernandez N; Caldas M; Garre A; Resina E; Puig I; O'Morain C; Megraud F; Gisbert JP
Helicobacter; 2020 Oct; 25(5):e12722. PubMed ID: 32656898
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.
Shaikh T; Fallone CA
Can J Gastroenterol Hepatol; 2016; 2016():7321574. PubMed ID: 27446864
[TBL] [Abstract][Full Text] [Related]
6. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
7. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera
Rodríguez de Santiago E; Martín de Argila de Prados C; Marcos Prieto HM; Jorge Turrión MÃ; Barreiro Alonso E; Flores de Miguel A; de la Coba Ortiz C; Rodríguez Escaja C; Pérez Álvarez G; Ferre Aracil C; Aguilera Castro L; García García de Paredes A; Rodríguez Pérez A; Albillos Martínez A
Helicobacter; 2017 Oct; 22(5):. PubMed ID: 28771880
[TBL] [Abstract][Full Text] [Related]
8. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
[TBL] [Abstract][Full Text] [Related]
9. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
Zagari RM; Romiti A; Ierardi E; Gravina AG; Panarese A; Grande G; Savarino E; Maconi G; Stasi E; Eusebi LH; Farinati F; Conigliaro R; Bazzoli F; Romano M
Helicobacter; 2018 Aug; 23(4):e12502. PubMed ID: 29924430
[TBL] [Abstract][Full Text] [Related]
10. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
[TBL] [Abstract][Full Text] [Related]
11. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
Long X; Chen Q; Yu L; Liang X; Liu W; Lu H
Helicobacter; 2018 Jun; 23(3):e12485. PubMed ID: 29696736
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
Liang X; Xu X; Zheng Q; Zhang W; Sun Q; Liu W; Xiao S; Lu H
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):802-7.e1. PubMed ID: 23376004
[TBL] [Abstract][Full Text] [Related]
13. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
Gisbert JP; Barrio J; Modolell I; Molina-Infante J; Aisa AP; Castro-Fernández M; Rodrigo L; Cosme A; Gisbert JL; Fernández-Bermejo M; Marcos S; Marín AC; McNicholl AG
Dig Dis Sci; 2015 Feb; 60(2):458-64. PubMed ID: 25236423
[TBL] [Abstract][Full Text] [Related]
14. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
15. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
16. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
Prapitpaiboon H; Mahachai V; Vilaichone RK
Asian Pac J Cancer Prev; 2015; 16(10):4353-6. PubMed ID: 26028098
[TBL] [Abstract][Full Text] [Related]
17. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
[TBL] [Abstract][Full Text] [Related]
18. Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study.
Gu LY; Lin WW; Lu H; Chen XY; Ge ZZ; Li XB
Helicobacter; 2011 Aug; 16(4):284-8. PubMed ID: 21762267
[TBL] [Abstract][Full Text] [Related]
19. Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial.
Hsu PI; Tsay FW; Graham DY; Tsai TJ; Tsai KW; Kao JY; Peng NJ; Kuo CH; Kao SS; Wang HM; Lin TF; Wu DC;
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1427-1433. PubMed ID: 29609070
[TBL] [Abstract][Full Text] [Related]
20. Third-line and rescue therapy for refractory
de Moraes Andrade PV; Monteiro YM; Chehter EZ
World J Gastroenterol; 2023 Jan; 29(2):390-409. PubMed ID: 36687120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
